Importantly, although CHEK2 variant carriership was associated with an increased predisposition to high‐risk HMs, a HSCT from a donor harbouring these variants, including homozygous carriers, did not negatively affect HSCT outcomes over the 5‐year follow‐up period. Here, CHEK2 is linked to Haim-Munk syndrome.